Eli Lilly and Company LLY
1,183.46
1.57
0.13%
as of 25 Sep
- Market cap
- $1.11T
- P/E
- 39.7×
Follow LLY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Eli Lilly and Company (LLY) Current ratio
Eli Lilly and Company's current ratio at the end of the quarter to 30 June 2026 was 1.4×, down 0.2× from fiscal 2025 (1.6×). Over the past ten years it has ranged from 0.9× (fiscal 2023) to 1.7× (fiscal 2018); the current reading is higher than 91% of that period. That is in line with the Drug Manufacturers General industry median of 1.3× and below the Healthcare sector median of 3.0×.
Current ratio, annual
Annual
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 1.6× | 36.86% |
| FY2024 | 1.2× | 22.41% |
| FY2023 | 0.9× | (10.42%) |
| FY2022 | 1.1× | (14.16%) |
| FY2021 | 1.2× | (12.37%) |
| FY2020 | 1.4× | 20.16% |
| FY2019 | 1.2× | (32.64%) |
| FY2018 | 1.7× | 30.86% |
| FY2017 | 1.3× | (3.89%) |
| FY2016 | 1.4× | (10.04%) |
Quarterly
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 1.4× | (9.50%) |
| Mar 2026 | 1.5× | (5.21%) |
| Dec 2025 | 1.6× | 2.12% |
| Sep 2025 | 1.5× | 21.02% |
| 42 more quarters | Free account |
Against its own ten years
Low 0.9×
High 1.7×
Ten-year median
1.3×
Current reading's percentile
91
Current ratio against peers
| Company | Current ratio |
|---|---|
| AMGN Amgen Inc. compare | 1.4× |
| LLY Eli Lilly and Company | 1.4× |
| MRK Merck & Co., Inc. compare | 1.3× |
| PFE Pfizer Inc. compare | 1.3× |
| GILD Gilead Sciences, Inc. compare | 1.3× |
| JNJ Johnson & Johnson compare | 1.1× |
| AZN AstraZeneca PLC compare | 0.9× |
| NVS Novartis AG compare | 0.9× |
| ABBV AbbVie Inc. compare | 0.8× |
| Drug Manufacturers General industry median | 1.3× |
| Healthcare sector median | 3.0× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on LLY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement